ArticleAntimicrobial agents and chemotherapy2024
Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Pharmacokinetic-pharmacodynamic modeling using combined time-kill data for meropenem and colistin or polymyxin B combination effects inAntimicrobial agents and chemotherapy · 2026Pooled it
- Time-Dependent Degradation of Imipenem in Aqueous Solution and Its Impact on Antibacterial Activity.Antibiotics (Basel, Switzerland) · 2026Article
- Comprehensive Phenotypic Characterization of ClinicalInternational journal of molecular sciences · 2026Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Antibiotic dose-response curves can measure antibiotic activity againstAntimicrobial agents and chemotherapy · 2026Article
- Mechanistic insights into phthalylsulfacetamide-induced restoration of meropenem bactericidal activity in NDM-1-positive Escherichia coli.BMC microbiology · 2026Article
- Comparative Stability and Quality Assessment of Powder-Liquid Double-Chamber Bag Versus Traditional Meropenem Infusions: Implications for Critical Care and Individualized Dosing.Pharmaceutics · 2026Article
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Article
- Targeting Microorganisms in Lignocellulosic Biomass to Produce Biogas and Ensure Sanitation and Hygiene.Microorganisms · 2026Review
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- Antibiotic dose-response curves can measure antibiotic activity againstbioRxiv : the preprint server for biology · 2025Article
- Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter Baumannii.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Matrine Restores Colistin Efficacy AgainstMolecules (Basel, Switzerland) · 2025Article
- In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates ofAntibiotics (Basel, Switzerland) · 2025Article
- A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) ofAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam in combination with β-lactams to combatAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam to boost the clinical utility of standard of care β-lactams againstAntimicrobial agents and chemotherapy · 2025Article
- Mass spectrometry-guided discovery of novel GCPII inhibitor scaffolds.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 5 countries.
Jieqiang ZhouDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Yuli QianDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Yinzhi LangDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Yongzhen ZhangDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Xun TaoDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Bartolome MoyaServicio de Microbiología and Unidad de investigación, Hospital Universitario Son Espases, Instituto de investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.ORCID 0000-0001-6404-246X
Alaa R M SayedDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Cornelia B LandersdorferDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0003-0928-4743
Eunjeong ShinDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Carolin WerkmanDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Nicholas M SmithLaboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-0212-2787
Tae Hwan KimCollege of Pharmacy, Catholic University of Daegu, Gyeongsan, Gyeongbuk, South Korea.
Monika KumaraswamyDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-3867-4268
Beom Soo ShinSchool of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.ORCID 0000-0002-6706-5445
Brian T TsujiLaboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
Robert A BonomoDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Richard E LeeDepartment of Chemical Biology and Therapeutics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jürgen B BulittaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-7352-3097
University of Florida · USUniversity at Buffalo, State University of New York · USDaegu Catholic University · KRHealth Research Institute of the Balearic Islands · ESLouis Stokes Cleveland VA Medical Center · USMonash University · AUSt. Jude Children's Research Hospital · USSungkyunkwan University · KRUniversity of California San Diego · US
Funding
Combating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7MNovel Strategies for Antibiotic Combinations to Combat Gram-negative SuperbugsR01AI148560 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BULITTA, JURGEN BERND, TSUJI, BRIAN · 2020 to 2024
$3.9MNext-generation combination dosing strategies to combat resistant Acinetobacter baumanniiR01AI130185 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$3.4MNIAID NIH HHS R01 AI130185NIAID NIH HHS R01 AI136803NIAID NIH HHS R01 AI148560
Abstract
Non-clinical antibiotic development relies on
Indexed as
beta-Lactamase Inhibitorsbeta-LactamsAgarAnti-Bacterial AgentsChromatography, LiquidClavulanic AcidDoripenemImipenemMicrobial Sensitivity TestsPenicillinsTandem Mass SpectrometryWaterAgarAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamsClavulanic AcidDoripenemImipenemPenicillinsWateravibactamaztreonambeta-lactam stabilitycarbapenemsceftazidimecephalosporinsclavulanic acid/clavulanatepenicillinstazobactam and sulbactamticarcillin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.